Located in Tijuana and emphasizing integrative therapy pathways to treat cancer, Oasis of Hope offers treatments ranging from epigenetics to insulin potentiation chemotherapy. Oasis of Hope also provides access to leading-edge drug therapies, including those involving the administration of erbitux and rituxan.
The latter drug is employed in treating B-cell non-Hodgkin’s lymphoma and stands as the first FDA-approved cancer fighting therapeutic monoclonal antibody. This relatively recent therapy approach targets CD20 antigens on both malignant and normal B-Cells. This type of white blood cell lymphocyte is essential in producing antibodies. While the immune system naturally attacks and eliminates marked B-cells, it does not attack the young stem cells in the bone marrow which do not possess the CD20 antigen. This enables the regeneration of healthy B-cells following treatment.
Erbitux is used to address neck, head, and colorectal cancers through targeting malignant cells that contain the epidermal growth factor receptor (EGFR). Inhibiting the activity of EGFR, erbitux selectively blocks signals that generate cancerous growth and also triggers an immune response against these cells.
No comments:
Post a Comment